期刊文献+

焦磷酸测序和双脱氧测序法检测结直肠癌患者K-ras基因突变的对比研究 被引量:5

A Comparison Between Pyrosequencing and Dideoxy Sequencing for K-ras Mutation Detection in Patients with Colorectal Cancer
原文传递
导出
摘要 [目的]探讨不同方法学对结直肠癌K-ras基因点突变检测结果的影响。[方法]对60例结直肠癌患者石蜡包埋组织样本进行K-ras基因第12、13位密码子突变检测,检测分别采用焦磷酸测序法及双脱氧测序法,并对结果进行对比分析。[结果]两种方法都能够检测到常见的突变类型,但由于两种方法的灵敏度不同,检出率焦磷酸测序法高于双脱氧测序,分别为33.3%(20/60)和25%(15/60)。经病理对肿瘤细胞比例分析发现,5例双脱氧测序法漏检标本中,肿瘤细胞比较少,不足20%。[结论]K-ras基因突变的检测过程中,标本肿瘤细胞的比例是影响结果的关键因素,检测前需要对标本进行病理评估,确保肿瘤细胞比例在50%以上。
出处 《肿瘤学杂志》 CAS 2012年第5期339-341,共3页 Journal of Chinese Oncology
  • 相关文献

参考文献11

  • 1Chang DZ, Kumar V,Ma Y,et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy [J]. J Hematol Oncol,2009,2:18.
  • 2Brink M,de Goeij AFPM,Weijenberg MP,et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study [J]. Carcinogenesis,2003,24(4): 703-710.
  • 3Stintzing S,Zheinemann V,Jung A,et al. The treatment of colorectal carcinoma with monoclonal antibodies:the im- portance of KRAS mutation analysis and EGFR status [J]. Dtsch Arztebl Int,2009,106(12): 202-206.
  • 4Allegra CJ,Jessup JM,Somerfield MR,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to an- ti-epidermal growth factor receptor monoclonal antibody therapy [J]. J Clin 0ncol,2009,27(2): 1-6.
  • 5Bjorheim J,Lystad S,Lindblom A,et al. Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis,constant denaturant capillaryelectrophoresis and allele specific polymerase chain reaction [J]. Mutat Res, 1998,403(1-2): 103-112.
  • 6Poehlmann A,Kuester D,Meyer F,et al. K-ras mutation detection in colorectal cancer using the pyrosequencing technique [J]. Pathol Res Prac,2007,203(7): 489-497.
  • 7陈婕,郭兴中,朱凡,邹媛,白法安,方国伟.焦磷酸测序法检测结直肠癌患者k-ras基因突变[J].中华检验医学杂志,2010,33(6):538-540. 被引量:1
  • 8De Roock W,Jonker DJ,Di Nicolantonio F,et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab [J]. JAMA,2010,304(16): 1812-1820.
  • 9van Krieken J HJ M,Jung A,Kirchner T,et al. KRA5 mutation testing for predicting response to anti-EGFR therapy for col- orectal carcioma: proposal for an European quality assur- ance program[J]. Virchows Arch,2008,453(5): 417-431.
  • 10黄唯,王安,陈渝萍,梁华敏,郭婷婷.VHL、NFκB和CXCR4状态与结肠癌肝转移的关系[J].肿瘤学杂志,2009,15(7):661-664. 被引量:2

二级参考文献43

  • 1叶建新,许东坡,李心翔.散发性结、直肠癌APC基因杂合缺失和突变的研究[J].中华实验外科杂志,2004,21(10):1209-1211. 被引量:9
  • 2高枫,唐卫中,李卫.中国人散发性大肠癌K-ras基因突变的研究[J].中华实验外科杂志,2005,22(1):65-67. 被引量:22
  • 3葛剑徽.焦磷酸测序技术的原理及应用[J].科技资讯,2006,4(4):216-217. 被引量:3
  • 4Abraham SC, Nubukawa B, Giardicllo FM, et al. Fundic gland polyps in familial adenomatous polyposis:neoplasms with frequent somatic adenomatous polyposis coli gene alterations[J]. Am J Pathol, 2000, 157(3):747-754.
  • 5Herrera L, Kakati S, Gibas L, et al. Gardner syndrome in a man with an interstitial deletion of 5q [J]. Am J Med Genet, 1986, 25(3) :473-476.
  • 6Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics[J]. Hum Pathol, 1998, 29(5) :469-475.
  • 7Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/ beta-catenin pathway in ulcerative colitis-related colorectal carcinomas:a mutational analysis [J]. Cancer, 2002, 94 (5) : 1421-1427.
  • 8Chop AM, Abraham CL, Adrian TE, et al. hnmunodetection of the presence or absence of full-length APC gene product in human colonic tissues [J]. Anticancer Res, 1995, 15(3) : 991-997.
  • 9Thliveris A.Long-range physical map and deletion characterization of the 1 100kb Notl restriction fragment harboring the APC gene[J]. Genomics, 1996, 34(2):268-270.
  • 10Rubinfeld B, Albert I, Portiri F, et al. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly[J].Science,1996,272(5264) : 1023-1026.

共引文献13

同被引文献94

  • 1沈琳.转移性结直肠癌靶向治疗个体化选择[J].肿瘤研究与临床,2008,20(8):507-508. 被引量:3
  • 2夏曙,于世英.抑制PI3K/Akt通路提高HeLa细胞化疗效果的实验研究[J].肿瘤防治研究,2006,33(3):156-158. 被引量:8
  • 3高凤兰.直肠癌C-erbB-2、nm23蛋白表达与预后的关系[J].世界华人消化杂志,2006,14(10):1015-1018. 被引量:7
  • 4Siddiqui AD,Piperdi B.KRAS mutation in colon cancer:a marker of resistance to EGFR-I therapy [J].Ann Surg On- col, 2010,17(4):1168-1176.
  • 5Zuo YX,Cao J,Zhu GS,et al. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer[J]. BMC Med Genet,2010,11:34-43.
  • 6Chang YS, Yeh KT, Chang TJ, et al. Fast simultaneous de- tection of K-RAS mutations in colorectal cancer [J]. BMC Cancer, 2009,9 : 179.
  • 7Soulieres D, Greer W, Magliocco AM, et al.KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies[J].Curr Oncol, 2010,17(1) :S31-40.
  • 8De Roock W,Jonker DJ,Di Nicolantonio F.Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treat- ed with cetuximab[J].JAMA, 2010,304(16): 1812-1820.
  • 9Souglakos J,Philips J,Wang R,et al.Prognostic and pre- dictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer [J]. Br J Cancer,2009,101(3):465-472.
  • 10Cappuzzo F,Varella-Garcia M,Finocchiaro G,et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients[J].Br J Cancer, 2008,99(1): 83-89.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部